Skip to main content
EOLS
NASDAQ Life Sciences

Evolus Achieves Second Consecutive Quarter of Positive Adjusted EBITDA and Terminates $50M ATM Program

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$5.65
Mkt Cap
$363.035M
52W Low
$3.86
52W High
$12.28
52W Position info
46% above low
Off High info
54% below high
Rel. Volume info
2.0× avg
Market data snapshot near publication time

EOLS sits 46% above its 52-week low of $3.86 on elevated volume (2.0× avg).

Summary

Evolus reported positive Adjusted EBITDA for Q1 2026, terminated a $50 million ATM program without selling shares, and reaffirmed its full-year guidance, signaling improved financial health and reduced dilution risk.


Key Events · Earnings and Guidance · EOLS

  • Achieves Positive Adjusted EBITDA

    Evolus reported $0.6 million in Adjusted EBITDA for the first quarter of 2026, marking the second consecutive quarter of profitability and a significant improvement from a $5.5 million loss in the prior year period.

  • Terminates $50 Million ATM Program

    The company terminated its 'at-the-market' sales agreement, which had authorized the sale of up to $50.0 million in common stock. No shares were sold under this program prior to termination, removing a potential dilutive overhang.

  • Reaffirms Full-Year 2026 Outlook

    Evolus reiterated its full-year 2026 net revenue guidance of $327 million to $337 million and continues to expect to achieve a low- to mid-single digit Adjusted EBITDA margin.

  • Discloses Potential Tariff Impact

    The company noted a potential 15% U.S. tariff on patented pharmaceuticals from South Korea, which could affect its Jeuveau® product starting September 29, 2026, but stated it has flexibility to mitigate near-to-medium term impacts.


Analysis · EOLS · Life Sciences

Evolus's Q1 2026 results demonstrate a significant operational turnaround, achieving positive Adjusted EBITDA for the second consecutive quarter, which is a key milestone for the company's financial health. The termination of the $50 million 'at-the-market' program, under which no shares were sold, removes a substantial potential dilutive overhang (approximately 13.7% of current market cap), signaling improved capital position or reduced need for immediate external financing. While a new potential tariff on Jeuveau® from South Korea presents a future risk, the company's stated mitigation strategies temper immediate concerns. The reaffirmation of full-year guidance further reinforces management's confidence in continued growth and profitability.

How filings like this one have moved

In the 30 days to Nov 5, 2026, 43.3% of the 1277 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.16%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, EOLS was trading at $5.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $363M. The 52-week trading range was $3.86 to $12.28. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

EOLS - Latest Insights

EOLS
Nov 04, 2026, 4:57 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $7.39
Real-time Price: $6.95 info
Change: -$0.445 (-6%) info
Market Cap: $458.72M info
EOLS
Nov 04, 2026, 4:05 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $7.47
Real-time Price: $6.95 info
Change: -$0.525 (-7%) info
Market Cap: $458.72M info
EOLS
Oct 02, 2026, 10:45 AM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $7.19
Real-time Price: $6.95 info
Change: -$0.240 (-3%) info
Market Cap: $458.72M info
EOLS
Aug 05, 2026, 4:56 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $6.53
Real-time Price: $6.95 info
Change: +$0.415 (+6%) info
Market Cap: $458.72M info
EOLS
Aug 05, 2026, 4:48 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $6.67
Real-time Price: $6.95 info
Change: +$0.275 (+4%) info
Market Cap: $458.72M info